Carbohydrate conjugates as delivery agents for oligonucleotides
The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):
1. A ligand-containing conjugate having the structure shown in formula (I):
wherein:
A and B are each independently for each occurrence O, N(R N ), or S;
one of X and Y is a solid support, optionally linked via a linker group, or a phosphoramidite, and the other of X and Y is a protecting group;
R is L 1 or has the structure shown in formula (II)-(V)
q 2A , q 2B , q 3A , q 3B , q 4A , q 4B , q 5A , q 5B and q 5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;
Q is absent, -(P 7 -Q 7 -R 7 ) p -T 7 - , or -T 7 -Q 7 -T T -B′-T 8 ′-Q 8 -T 8 -;
P 2A , P 2B , P 3A , P 3B , P 4A , P 4B , P 5A , P 5B , P 5C , P 7 , T 2A , T 2B , T 3A , T 3B , T 4A , T 4B , T 5A , T 5B , T 5C , T 7 , T 7′ , T 8 and T 8′ are each independently for each occurrence absent, CO, NH, O, S, OC(O), C(O)O, NHC(O), C(O)NH, CH 2 , CH 2 NH, NHCH 2 , OCH 2 or CH 2 O;
B′ is —CH 2 —N(B L )—CH 2 —;
B L is -T B -Q B -T B′ -R x ;
Q 2A , Q 2B , Q 3A , Q 3B , Q 4A , Q 4B , Q 5A , Q 5B , Q 5C , Q 7 , Q 8 and Q B are independently for each occurrence absent, alkylene, substituted alkylene and wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO 2 , N(R N ), C(R′)═C(R′), C≡C or C(O);
T B and T B′ are each independently for each occurrence absent, CO, NH, O, S, OC(O), C(O)O, NHC(O), C(O)NH, NHC(O)NH, NHC(O)O, OC(O)NH, CH 2 , CH 2 NH, NHCH 2 , OCH 2 , or CH 2 O;
R x is a lipophile, or a cationic lipid;
R 2A , R 2B , R 3A , R 3B , R 4A , R 4B , R 5A , R 5B , R 5c , and R 7 are each independently for each occurrence absent, NH, O, S, CH 2 , C(O)O, OC(O), C(O)NH, NHC(O), NHCH(R a )C(O), C(O)—CH(R a )—NH, CO, CH═N—O
or heterocyclyl;
L 1 , L 2A , L 2B , L 3A , L 3B , L 4A , L 4B , L 5A , L 5B and L 5C are each independently for each occurrence a carbohydrate or a derivative thereof having hydroxyl protecting group(s);
R′ and R″ are each independently H, C 1 -C 6 alkyl, OH, SH, or N(R N ) 2 ;
R N is independently for each occurrence methyl, ethyl, propyl, isopropyl, butyl or benzyl;
R a is H or amino acid side chain; and
p represents independently for each occurrence 0-20.
2. The ligand-containing conjugate of claim 1 , wherein:
A and B are each O;
one of X and Y is a solid support, a solid support linked via a —C(O)CH 2 CH 2 C(O)—group, or a phosphoramidite, and the other of X and Y is a hydroxyl protecting group;
R has the structure shown in formula (V);
Q is P 7 -Q 7 -T 7 ;
Q 7 is alkene; and
L 5A , L 5B , and L 5C are each independently for each occurrence a derivative of a carbohydrate, having hydroxyl protecting group(s).
3. The ligand-containing conjugate of claim 2 , wherein the carbohydrate is selected from the group consisting of galactose, galactosamine, N-acetylgalactosamine (GalNAc), D-galactosaminitol, mannose, mannosamine, mannose-6-phosphate, glucose, glucosamine, N-acetyl-glucosamine (GluNAc), glucose-6- phosphate, glucosaminitol, glucose glyceraldehyde, fucose, fucosamine, fuculose, lactose, allose, altrose, arabinose, cladinose, erythrose, erythrulose, fructose, D-fucitol, L-fucitol, L-glycero-D-mannos-heptose, glycerol, glycerone, gulose, idose, lyxose, psicose, quinovose, quinovosamine, rhamnose, rhamnitol, rhamnosamine, ribose, ribulose, sedoheptulose, sorbose, tagatose, talose, tartaric acid, threose, xylose, and xylulose.
4. The ligand-containing conjugate of claim 3 , wherein the carbohydrate is N-acetylgalactosamine (GalNAc).
5. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is selected from the group consisting of:
wherein:
each of m, n, p, q, s, and t is independently an interger of 1 to 17, and
each of R′ and R″ is independently H or alkyl.
6. The ligand-containing conjugate of claim 2 , wherein the ligand-containing conjugate has the structure of
wherein n is an interger of 1 to 17, X is a solid support or a solid support linked via a —C(O)CH 2 CH 2 C(O)—group, and Y is a hydroxyl protecting group.
7. The ligand-containing conjugate of claim 2 , wherein the ligand-containing conjugate is
wherein
is a solid support.
8. The ligand-containing conjugate of claim 2 , wherein the ligand-containing conjugate is
wherein
wherein is a solid support.
9. The ligand-containing conjugate of claim 2 , wherein the ligand-containing conjugate is
wherein
is a solid support.
10. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
wherein
is a solid support.
11. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
wherein
is a solid support.
12. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
wherein
is a solid support.
13. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
wherein
is a solid support.
14. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
wherein
is a solid support.
15. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
16. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
wherein
is a solid support.
17. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
wherein
is a solid support.
18. The ligand-containing conjugate of claim 1 , wherein the ligand-containing conjugate is
19. A method of synthesizing a ligand-conjugated oligonucleotide, comprising:
providing a ligand-containing conjugate of claim 2 , and
conjugating the ligand-containing conjugate to an oligonucleotide.
20. The method of claim 19 , wherein conjugating the ligand-containing conjugate is carried out by growing the oligonucleotide to the ligand-containing conjugate.